AstraZeneca: positive data in gastric cancer
(CercleFinance.com) - AstraZeneca announced on Friday that a combination of its Imfinzi immunotherapy and chemotherapy has demonstrated clinical benefit in the treatment of gastric and oesogastric junction cancers.
According to the preliminary results of a phase III study, this combination administered as neoadjuvant treatment (before surgery) produced a significant improvement both statistically and clinically in terms of complete response, compared with chemotherapy alone.
The trial enrolled patients with operable early or locally advanced cancers of the stomach or oesogastric junction.
The study is to continue as planned in order to assess the primary endpoints of event-free survival and overall survival.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
According to the preliminary results of a phase III study, this combination administered as neoadjuvant treatment (before surgery) produced a significant improvement both statistically and clinically in terms of complete response, compared with chemotherapy alone.
The trial enrolled patients with operable early or locally advanced cancers of the stomach or oesogastric junction.
The study is to continue as planned in order to assess the primary endpoints of event-free survival and overall survival.
Copyright (c) 2023 CercleFinance.com. All rights reserved.